Int J Nanomedicine:钛的表面纳米空穴可调节巨噬细胞活性

2018-12-30 MedSci MedSci原创

纳米级表面改性常用于改善医学相关材料的生物相容性。免疫细胞,例如巨噬细胞,在植入后的初始愈合事件中起关键作用。为了更好地了解巨噬细胞对纳米形貌的反应,我们将U937衍生的巨噬细胞暴露于通过简单化学纳米空穴化过程产生的独特的介孔钛表面(TiNano),并将机械抛光的钛(TiPolished)和玻璃盖玻片(玻璃)表面暴露于控制。评估细胞数量和形态。分析骨桥蛋白的表达和促炎性SPARC蛋白及其稳定蛋白1

纳米级表面改性常用于改善医学相关材料的生物相容性。免疫细胞,例如巨噬细胞,在植入后的初始愈合事件中起关键作用。

为了更好地了解巨噬细胞对纳米形貌的反应,我们将U937衍生的巨噬细胞暴露于通过简单化学纳米空穴化过程产生的独特的介孔钛表面(TiNano),并将机械抛光的钛(TiPolished)和玻璃盖玻片(玻璃)表面暴露于控制。评估细胞数量和形态。分析骨桥蛋白的表达和促炎性SPARC蛋白及其稳定蛋白1受体的表达。还测量了炎症相关细胞因子和趋化因子的释放。

结果显示,与两个对照表面相比,TiNano上的U937细胞较少,并且这些细胞在长丝状伪足下表现出更圆润的形态。细胞显示出点状肌动蛋白分布区域,表明形成了podosomes。在检查的三种蛋白质中,只有骨桥蛋白的免疫荧光信号明显减少。无论底物如何,细胞因子测定揭示了所分析的多个分子的表达水平的重要变化以及TiNano表面在许多趋化因子中的下调。

综上所述,这些结果表明,巨噬细胞感知并响应由纳米腔表面产生的物理化学提示,引发细胞和分子变化,与较小的炎症倾向一致。鉴于先前报道的这种中孔表面对成骨活性的有益结果,可以推测其引起的巨噬细胞反应的调节也可能有助于初始骨整合事件。

原始出处:

Marianne B Ariganello, Dainelys Guadarrama Bello, et al., Surface nanocavitation of titanium modulates macrophage activity. Int J Nanomedicine. 2018; 13: 8297–8308.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679744, encodeId=d0ac16e9744fc, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Tue Oct 01 17:27:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773751, encodeId=d2bd1e73751ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 26 06:27:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858921, encodeId=6e241858921e3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Nov 07 10:27:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577640, encodeId=e62815e76406a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609446, encodeId=a4bb160944682, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-10-01 30397613
  2. [GetPortalCommentsPageByObjectIdResponse(id=1679744, encodeId=d0ac16e9744fc, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Tue Oct 01 17:27:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773751, encodeId=d2bd1e73751ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 26 06:27:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858921, encodeId=6e241858921e3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Nov 07 10:27:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577640, encodeId=e62815e76406a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609446, encodeId=a4bb160944682, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-03-26 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1679744, encodeId=d0ac16e9744fc, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Tue Oct 01 17:27:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773751, encodeId=d2bd1e73751ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 26 06:27:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858921, encodeId=6e241858921e3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Nov 07 10:27:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577640, encodeId=e62815e76406a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609446, encodeId=a4bb160944682, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-11-07 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1679744, encodeId=d0ac16e9744fc, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Tue Oct 01 17:27:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773751, encodeId=d2bd1e73751ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 26 06:27:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858921, encodeId=6e241858921e3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Nov 07 10:27:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577640, encodeId=e62815e76406a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609446, encodeId=a4bb160944682, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1679744, encodeId=d0ac16e9744fc, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Tue Oct 01 17:27:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773751, encodeId=d2bd1e73751ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 26 06:27:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858921, encodeId=6e241858921e3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Nov 07 10:27:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577640, encodeId=e62815e76406a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609446, encodeId=a4bb160944682, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 16:27:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]